Answers are grounded in this paper and cite their sources.
Background: Pregnant women are at increased risk of complications when infected by SARS-CoV-2, hence the recommendations for vaccines against COVID-19 during pregnancy. Post-marketing safety surveillance is crucial for this subpopulation typically excluded from clinical trials. Our objective was to assess the risk of adverse events of special interest (AESI) after mRNA vaccination during pregnancy using the French National Health Data System. Methods: ). We calculated OE ratios for events after the homologous vaccination schemes during 2021-2023 with mRNA vaccines (BNT: BTN162b2 or MOD: mRNA-1273). Our signal criterion was a lower bound of the bilateral 95% confidence interval (LB95CI) greater than 1. Sensitivity analyses explored alternative definitions of AESIs and follow-up, including accounting for SARS-Cov-2 infection, and assessed the consistency of results with general population data. Findings: (LB95CI = 1.1), based on 3 and 2 observed cases, respectively. Consistent results were found with sensitivity analyses. Interpretation: This work did not evidence any safety signal after mRNA vaccination against COVID-19 for AESI during pregnancy. It contributes to the growing body of evidence regarding its safety. Funding: This study did not receive any specific grant.
No takes yet. Share an insight, caveat, or question.
Escolano et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: